|
|
|
|
A detailed exploration of challenges in advancing stem cell programs to GMP, highlighting strategies to control variability, strengthen process design, and support reliable clinical‑stage manufacturing.
|
|
|
|
|
Early, phase-appropriate CMC planning is critical for advanced therapy success. Proactively managing regulatory risks and applying Quality by Design principles secures a clear path to market.
|
|
|
|
|
View a scalable, open-access AAV9 manufacturing process improving yield, purity, and consistency through optimized transfection and downstream purification for clinical-grade gene therapy production.
|
|
|
|
|
|
|
An integrated platform unites synthetic DNA production with advanced therapy development and GMP manufacturing, streamlining workflows while improving speed, scalability, and control.
|
|
|
|
|
Optimized synthetic DNA enables scalable gene and RNA therapies with improved stability, expression, and delivery, supporting advanced applications across viral, non-viral, and vaccine platforms.
|
|
|
